Patient Inclusion Criteria

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria: Written patient informed consent or assent must be obtained prior to start of treatment. - Patients aged ≥ 6 years - Patients clinically diagnosed with SARS-CoV-2 infection, either through positive serum antibodies (IgM or IgG); or by PCR; or by other approved diagnostic methodology. Patients with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and SARS-CoV-2 test pending) may be included. - Adult and adolescent patients (≥12years), who meet one of the below criteria - Respiratory frequency ≥ 30/min - Oxygen saturation ≤ 93% on room air (FiO2=0.21) - Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) <300mmHg(1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m). AND -- Patients with lung imaging showing pulmonary infiltrates (chest X-ray or CT scan) Pediatric patients (≥6-<12 years) who meet one of the below criteria (where appropriate): - Shortness of breath - Oxygen saturation <92% on room air (Fi)2=0.21) - Labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis, intermittent apnea. - Lethargy or convulsions - Refusal to eat or difficulty with feeding; signs of dehydration

Patient Exclusion Criteria

- Patients eligible for this Treatment Plan must not meet any of the following criteria: - History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib - Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation. - Pregnant or nursing (lactating) women. - Patients who are NOT able to understand and to comply with treatment instructions and requirements unless health care proxy is able to provide consent.